Insider Accumulation: Kevin Tang Acquires $891k of Fulcrum Therapeutics Shares Amid Clinical Setbacks
Kevin Tang, a major shareholder in Fulcrum Therapeutics, Inc. (NASDAQ: FULC), has executed a series of substantial purchases of the company's common stock. The acquisitions, totaling approximately $891,067, were conducted through Tang Capital Management LLC and its affiliated entities between July 13 and July 15, 2026. This insider buying activity …